Chronic myeloproliferative disorders are rare hematological malignances that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow.
The available drugs have not shown disease-modifying activity and are still largely inadequate for managing major unmet needs, which include prevention of hematological progression, normalization of life span, reduction of cardiovascular complications, and improved quality of life. Strong unmet needs within the market present a key opportunity to develop breakthrough first-in-class therapies.
Market Analysis and Insights: Global Myeloproliferative Disorders Drugs Market
The global Myeloproliferative Disorders Drugs market size is projected to reach US$ 7389.7 million by 2026, from US$ 6589.8 million in 2020, at a CAGR of 1.9% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myeloproliferative Disorders Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myeloproliferative Disorders Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myeloproliferative Disorders Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myeloproliferative Disorders Drugs market.
Myeloproliferative Disorders Drugs Breakdown Data by Type
Ph+ CML
Ph- MPN
Myeloproliferative Disorders Drugs Breakdown Data by Application
Hospitals
Pharmacy
Based on regional and country-level analysis, the Myeloproliferative Disorders Drugs market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Myeloproliferative Disorders Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
Celgene
Bristol-Myers Squibb
Gamida Cell
Incyte
Geron
Promedior
Johnson and Johnson
...
The available drugs have not shown disease-modifying activity and are still largely inadequate for managing major unmet needs, which include prevention of hematological progression, normalization of life span, reduction of cardiovascular complications, and improved quality of life. Strong unmet needs within the market present a key opportunity to develop breakthrough first-in-class therapies.
Market Analysis and Insights: Global Myeloproliferative Disorders Drugs Market
The global Myeloproliferative Disorders Drugs market size is projected to reach US$ 7389.7 million by 2026, from US$ 6589.8 million in 2020, at a CAGR of 1.9% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myeloproliferative Disorders Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myeloproliferative Disorders Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myeloproliferative Disorders Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myeloproliferative Disorders Drugs market.
Myeloproliferative Disorders Drugs Breakdown Data by Type
Ph+ CML
Ph- MPN
Myeloproliferative Disorders Drugs Breakdown Data by Application
Hospitals
Pharmacy
Based on regional and country-level analysis, the Myeloproliferative Disorders Drugs market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Myeloproliferative Disorders Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
Celgene
Bristol-Myers Squibb
Gamida Cell
Incyte
Geron
Promedior
Johnson and Johnson
...
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myeloproliferative Disorders Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Ph+ CML
1.2.3 Ph- MPN
1.3 Market by Application
1.3.1 Global Myeloproliferative Disorders Drugs Market Share by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Myeloproliferative Disorders Drugs Market Perspective (2015-2026)
2.2 Global Myeloproliferative Disorders Drugs Growth Trends by Regions
2.2.1 Myeloproliferative Disorders Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Myeloproliferative Disorders Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Myeloproliferative Disorders Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myeloproliferative Disorders Drugs Players by Market Size
3.1.1 Global Top Myeloproliferative Disorders Drugs Players by Revenue (2015-2020)
3.1.2 Global Myeloproliferative Disorders Drugs Revenue Market Share by Players (2015-2020)
3.2 Global Myeloproliferative Disorders Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Myeloproliferative Disorders Drugs Revenue
3.4 Global Myeloproliferative Disorders Drugs Market Concentration Ratio
3.4.1 Global Myeloproliferative Disorders Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myeloproliferative Disorders Drugs Revenue in 2019
3.5 Key Players Myeloproliferative Disorders Drugs Area Served
3.6 Key Players Myeloproliferative Disorders Drugs Product Solution and Service
3.7 Date of Enter into Myeloproliferative Disorders Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myeloproliferative Disorders Drugs Breakdown Data by Type (2015-2026)
4.1 Global Myeloproliferative Disorders Drugs Historic Market Size by Type (2015-2020)
4.2 Global Myeloproliferative Disorders Drugs Forecasted Market Size by Type (2021-2026)
5 Myeloproliferative Disorders Drugs Breakdown Data by Application (2015-2026)
5.1 Global Myeloproliferative Disorders Drugs Historic Market Size by Application (2015-2020)
5.2 Global Myeloproliferative Disorders Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Myeloproliferative Disorders Drugs Market Size (2015-2026)
6.2 North America Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
6.3 North America Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)
6.4 North America Myeloproliferative Disorders Drugs Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Myeloproliferative Disorders Drugs Market Size (2015-2026)
7.2 Europe Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
7.3 Europe Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)
7.4 Europe Myeloproliferative Disorders Drugs Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Myeloproliferative Disorders Drugs Market Size (2015-2026)
8.2 China Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
8.3 China Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)
8.4 China Myeloproliferative Disorders Drugs Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Myeloproliferative Disorders Drugs Market Size (2015-2026)
9.2 Japan Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
9.3 Japan Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)
9.4 Japan Myeloproliferative Disorders Drugs Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Myeloproliferative Disorders Drugs Market Size (2015-2026)
10.2 Southeast Asia Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
10.3 Southeast Asia Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)
10.4 Southeast Asia Myeloproliferative Disorders Drugs Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 Celgene
11.1.1 Celgene Company Details
11.1.2 Celgene Business Overview
11.1.3 Celgene Myeloproliferative Disorders Drugs Introduction
11.1.4 Celgene Revenue in Myeloproliferative Disorders Drugs Business (2015-2020))
11.1.5 Celgene Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Myeloproliferative Disorders Drugs Introduction
11.2.4 Bristol-Myers Squibb Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Gamida Cell
11.3.1 Gamida Cell Company Details
11.3.2 Gamida Cell Business Overview
11.3.3 Gamida Cell Myeloproliferative Disorders Drugs Introduction
11.3.4 Gamida Cell Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
11.3.5 Gamida Cell Recent Development
11.4 Incyte
11.4.1 Incyte Company Details
11.4.2 Incyte Business Overview
11.4.3 Incyte Myeloproliferative Disorders Drugs Introduction
11.4.4 Incyte Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
11.4.5 Incyte Recent Development
11.5 Geron
11.5.1 Geron Company Details
11.5.2 Geron Business Overview
11.5.3 Geron Myeloproliferative Disorders Drugs Introduction
11.5.4 Geron Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
11.5.5 Geron Recent Development
11.6 Promedior
11.6.1 Promedior Company Details
11.6.2 Promedior Business Overview
11.6.3 Promedior Myeloproliferative Disorders Drugs Introduction
11.6.4 Promedior Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
11.6.5 Promedior Recent Development
11.7 Johnson and Johnson
11.7.1 Johnson and Johnson Company Details
11.7.2 Johnson and Johnson Business Overview
11.7.3 Johnson and Johnson Myeloproliferative Disorders Drugs Introduction
11.7.4 Johnson and Johnson Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
11.7.5 Johnson and Johnson Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myeloproliferative Disorders Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Ph+ CML
1.2.3 Ph- MPN
1.3 Market by Application
1.3.1 Global Myeloproliferative Disorders Drugs Market Share by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Myeloproliferative Disorders Drugs Market Perspective (2015-2026)
2.2 Global Myeloproliferative Disorders Drugs Growth Trends by Regions
2.2.1 Myeloproliferative Disorders Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Myeloproliferative Disorders Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Myeloproliferative Disorders Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myeloproliferative Disorders Drugs Players by Market Size
3.1.1 Global Top Myeloproliferative Disorders Drugs Players by Revenue (2015-2020)
3.1.2 Global Myeloproliferative Disorders Drugs Revenue Market Share by Players (2015-2020)
3.2 Global Myeloproliferative Disorders Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Myeloproliferative Disorders Drugs Revenue
3.4 Global Myeloproliferative Disorders Drugs Market Concentration Ratio
3.4.1 Global Myeloproliferative Disorders Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myeloproliferative Disorders Drugs Revenue in 2019
3.5 Key Players Myeloproliferative Disorders Drugs Area Served
3.6 Key Players Myeloproliferative Disorders Drugs Product Solution and Service
3.7 Date of Enter into Myeloproliferative Disorders Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myeloproliferative Disorders Drugs Breakdown Data by Type (2015-2026)
4.1 Global Myeloproliferative Disorders Drugs Historic Market Size by Type (2015-2020)
4.2 Global Myeloproliferative Disorders Drugs Forecasted Market Size by Type (2021-2026)
5 Myeloproliferative Disorders Drugs Breakdown Data by Application (2015-2026)
5.1 Global Myeloproliferative Disorders Drugs Historic Market Size by Application (2015-2020)
5.2 Global Myeloproliferative Disorders Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Myeloproliferative Disorders Drugs Market Size (2015-2026)
6.2 North America Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
6.3 North America Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)
6.4 North America Myeloproliferative Disorders Drugs Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Myeloproliferative Disorders Drugs Market Size (2015-2026)
7.2 Europe Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
7.3 Europe Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)
7.4 Europe Myeloproliferative Disorders Drugs Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Myeloproliferative Disorders Drugs Market Size (2015-2026)
8.2 China Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
8.3 China Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)
8.4 China Myeloproliferative Disorders Drugs Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Myeloproliferative Disorders Drugs Market Size (2015-2026)
9.2 Japan Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
9.3 Japan Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)
9.4 Japan Myeloproliferative Disorders Drugs Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Myeloproliferative Disorders Drugs Market Size (2015-2026)
10.2 Southeast Asia Myeloproliferative Disorders Drugs Market Size by Type (2015-2020)
10.3 Southeast Asia Myeloproliferative Disorders Drugs Market Size by Application (2015-2020)
10.4 Southeast Asia Myeloproliferative Disorders Drugs Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 Celgene
11.1.1 Celgene Company Details
11.1.2 Celgene Business Overview
11.1.3 Celgene Myeloproliferative Disorders Drugs Introduction
11.1.4 Celgene Revenue in Myeloproliferative Disorders Drugs Business (2015-2020))
11.1.5 Celgene Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Myeloproliferative Disorders Drugs Introduction
11.2.4 Bristol-Myers Squibb Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Gamida Cell
11.3.1 Gamida Cell Company Details
11.3.2 Gamida Cell Business Overview
11.3.3 Gamida Cell Myeloproliferative Disorders Drugs Introduction
11.3.4 Gamida Cell Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
11.3.5 Gamida Cell Recent Development
11.4 Incyte
11.4.1 Incyte Company Details
11.4.2 Incyte Business Overview
11.4.3 Incyte Myeloproliferative Disorders Drugs Introduction
11.4.4 Incyte Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
11.4.5 Incyte Recent Development
11.5 Geron
11.5.1 Geron Company Details
11.5.2 Geron Business Overview
11.5.3 Geron Myeloproliferative Disorders Drugs Introduction
11.5.4 Geron Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
11.5.5 Geron Recent Development
11.6 Promedior
11.6.1 Promedior Company Details
11.6.2 Promedior Business Overview
11.6.3 Promedior Myeloproliferative Disorders Drugs Introduction
11.6.4 Promedior Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
11.6.5 Promedior Recent Development
11.7 Johnson and Johnson
11.7.1 Johnson and Johnson Company Details
11.7.2 Johnson and Johnson Business Overview
11.7.3 Johnson and Johnson Myeloproliferative Disorders Drugs Introduction
11.7.4 Johnson and Johnson Revenue in Myeloproliferative Disorders Drugs Business (2015-2020)
11.7.5 Johnson and Johnson Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
